Brief: Neurovive Pharmaceutical Q4 Pre-Tax Loss Widens To SEK 20.0 Mln

Abliva AB

28/02/2019 07:43

Feb 28 (Reuters) - NeuroVive Pharmaceutical AB  NVP.ST :
    * Q4 NET SALES SEK 5,000 VERSUS SEK 0 YEAR AGO
    * Q4 PRE-TAX LOSS SEK 20.0 MILLION VERSUS LOSS SEK 14.8
MILLION
YEAR AGO
    * NEUROVIVE PHARMACEUTICAL - CURRENT FOCUS IS NV556, AIM IS
TO BE
ABLE TO SIGN OUT-LICENSING DEAL SOMETIME IN H1 2019

Source text for Eikon:  ID:nWkr5gd9sW 
Further company coverage:  NVP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))